Collegium Pharmaceutical Total Assets Growth & History (COLL)
Collegium Pharmaceutical's total assets was $1.66B for fiscal 2025.
View full Collegium Pharmaceutical company overviewCollegium Pharmaceutical annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.66B | −$6.8M | −0.41% |
| 2024 | 2024-12-31 | $1.66B | $520.3M | +45.51% |
| 2023 | 2023-12-31 | $1.14B | −$30.8M | −2.63% |
| 2022 | 2022-12-31 | $1.17B | $482.1M | +69.65% |
| 2021 | 2021-12-31 | $692.1M | $48.2M | +7.49% |
| 2020 | 2020-12-31 | $643.8M | $337.5M | +110.20% |
| 2019 | 2019-12-31 | $306.3M | $15.1M | +5.17% |
| 2018 | 2018-12-31 | $291.2M | $155.7M | +114.83% |
| 2017 | 2017-12-31 | $135.6M | −$26.4M | −16.32% |
| 2016 | 2016-12-31 | $162.0M | $64.3M | +65.80% |
| 2015 | 2015-12-31 | $97.7M | $92.6M | +1819.80% |
| 2014 | 2014-12-31 | $5.1M | — | — |
Collegium Pharmaceutical quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.14B | $543.2M | +34.10% |
| Q1 2026 | 2026-03-31 | $1.65B | $20.6M | +1.26% |
| Q4 2025 | 2025-12-31 | $1.66B | −$6.8M | −0.41% |
| Q3 2025 | 2025-09-30 | $1.61B | −$27.8M | −1.70% |
| Q2 2025 | 2025-06-30 | $1.59B | $539.2M | +51.19% |
| Q1 2025 | 2025-03-31 | $1.63B | $517.1M | +46.41% |
| Q4 2024 | 2024-12-31 | $1.66B | $520.3M | +45.51% |
| Q3 2024 | 2024-09-30 | $1.64B | $457.6M | +38.86% |
| Q2 2024 | 2024-06-30 | $1.05B | −$160.5M | −13.22% |
| Q1 2024 | 2024-03-31 | $1.11B | −$100.0M | −8.24% |
| Q4 2023 | 2023-12-31 | $1.14B | −$30.8M | −2.63% |
| Q3 2023 | 2023-09-30 | $1.18B | −$23.4M | −1.95% |
| Q2 2023 | 2023-06-30 | $1.21B | −$31.7M | −2.54% |
| Q1 2023 | 2023-03-31 | $1.21B | −$31.8M | −2.56% |
| Q4 2022 | 2022-12-31 | $1.17B | $482.1M | +69.65% |
| Q3 2022 | 2022-09-30 | $1.20B | $459.1M | +61.89% |
| Q2 2022 | 2022-06-30 | $1.25B | $531.8M | +74.51% |
| Q1 2022 | 2022-03-31 | $1.25B | $600.1M | +92.88% |
| Q4 2021 | 2021-12-31 | $692.1M | $48.2M | +7.49% |
| Q3 2021 | 2021-09-30 | $741.8M | $98.0M | +15.21% |
| Q2 2021 | 2021-06-30 | $713.7M | $66.9M | +10.34% |
| Q1 2021 | 2021-03-31 | $646.1M | $11.3M | +1.78% |
| Q4 2020 | 2020-12-31 | $643.8M | $337.5M | +110.20% |
| Q3 2020 | 2020-09-30 | $643.8M | $339.9M | +111.81% |
| Q2 2020 | 2020-06-30 | $646.9M | $345.3M | +114.49% |
| Q1 2020 | 2020-03-31 | $634.8M | $340.4M | +115.65% |
| Q4 2019 | 2019-12-31 | $306.3M | $15.1M | +5.17% |
| Q3 2019 | 2019-09-30 | $304.0M | −$342.5M | −52.98% |
| Q2 2019 | 2019-06-30 | $301.6M | −$371.7M | −55.21% |
| Q1 2019 | 2019-03-31 | $294.4M | −$401.9M | −57.72% |
| Q4 2018 | 2018-12-31 | $291.2M | $155.7M | +114.83% |
| Q3 2018 | 2018-09-30 | $646.5M | $523.8M | +427.02% |
| Q2 2018 | 2018-06-30 | $673.3M | $548.8M | +440.76% |
| Q1 2018 | 2018-03-31 | $696.3M | $556.4M | +397.88% |
| Q4 2017 | 2017-12-31 | $135.6M | −$26.4M | −16.32% |
| Q3 2017 | 2017-09-30 | $122.7M | $23.9M | +24.26% |
| Q2 2017 | 2017-06-30 | $124.5M | $4.8M | +4.00% |
| Q1 2017 | 2017-03-31 | $139.8M | $3.5M | +2.57% |
| Q4 2016 | 2016-12-31 | $162.0M | $64.3M | +65.80% |
| Q3 2016 | 2016-09-30 | $98.7M | −$8.3M | −7.78% |
| Q2 2016 | 2016-06-30 | $119.7M | $5.5M | +4.86% |
| Q1 2016 | 2016-03-31 | $136.3M | $89.0M | +187.69% |
| Q4 2015 | 2015-12-31 | $97.7M | $92.6M | +1819.80% |
| Q3 2015 | 2015-09-30 | $107.0M | — | — |
| Q2 2015 | 2015-06-30 | $114.2M | — | — |
| Q1 2015 | 2015-03-31 | $47.4M | — | — |
| Q4 2014 | 2014-12-31 | $5.1M | — | — |
Collegium Pharmaceutical total assets trends
Over the last five fiscal years, Collegium Pharmaceutical's total assets increased from $643.8M to $1.66B, a change of $1.01B. The latest reported quarter, Q2 2026, shows $2.14B.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Collegium Pharmaceutical source filings ↗